Advances in high-throughput genomic technologies coupled with a growing number of genomic results potentially useful in clinical care have led to ground-breaking genomic medicine implementation programs in various nations. Many of these innovative programs capitalize on unique local capabilities arising from the structure of their health care systems or their cultural or political milieu, as well as from unusual burdens of disease or risk alleles. Many such programs are being conducted in relative isolation and might benefit from sharing of approaches and lessons learned in other nations. The National Human Genome Research Institute recently brought together 25 of these groups from around the world to describe and compare projects, examine the current state of implementation and desired near-term capabilities, and identify opportunities for collaboration to promote the responsible implementation of genomic medicine.
In: Manolio , T A , Abramowicz , M , Al-Mulla , F , Anderson , W , Balling , R , Berger , A C , Bleyl , S , Chakravarti , A , Chantratita , W , Chisholm , R L , Dissanayake , V H W , Dunn , M , Dzau , V J , Han , B G , Hubbard , T , Kolbe , A , Korf , B , Kubo , M , Lasko , P , Leego , E , Mahasirimongkol , S , Majumdar , P P , Matthijs , G , McLeod , H L , Metspalu , A , Meulien , P , Miyano , S , Naparstek , Y , O'Rourke , P P , Patrinos , G P , Rehm , H L , Relling , M V , Rennert , G , Rodriguez , L L , Roden , D M , Shuldiner , A R , Sinha , S , Tan , P , Ulfendahl , M , Ward , R , Williams , M S , Wong , J E L , Green , E D & Ginsburg , G S 2015 , ' Global implementation of genomic medicine : We are not alone ' , Science Translational Medicine , vol. 7 , no. 290 , 290ps13 . https://doi.org/10.1126/scitranslmed.aab0194
Around the world, innovative genomic-medicine programs capitalize on singular capabilities arising from local health care systems, cultural or political milieus, and unusual selected risk alleles or disease burdens. Such individual eforts might beneft from the sharing of approaches and lessons learned in other locales. The U.S. National Human Genome Research Institute and the National Academy of Medicine recently brought together 25 of these groups to compare projects, to examine the current state of implementation and desired near-term capabilities, and to identify opportunities for collaboration that promote the responsible practice of genomic medicine. Eforts to coalesce these groups around concrete but compelling signature projects should accelerate the responsible implementation of genomic medicine in eforts to improve clinical care worldwide.
Around the world, innovative genomic-medicine programs capitalize on singular capabilities arising from local health care systems, cultural or political milieus, and unusual selected risk alleles or disease burdens. Such individual efforts might benefit from the sharing of approaches and lessons learned in other locales. The U.S. National Human Genome Research Institute and the National Academy of Medicine recently brought together 25 of these groups to compare projects, to examine the current state of implementation and desired near-term capabilities, and to identify opportunities for collaboration that promote the responsible practice of genomic medicine. Efforts to coalesce these groups around concrete but compelling signature projects should accelerate the responsible implementation of genomic medicine in efforts to improve clinical care worldwide.